

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

Company name: Aposense **Website:** www.aposense.com

CEO name: Yuval Gottenstein **Cell phone number:** 054-6484723

Select a CATEGORY: Biotech/Pharma

Select up to two SESSIONS per abstract from the list below

3. Are Cancer Therapeutics Fulfilling the Promise?
6. Facts and Myths on Ex-Liver Delivery of Nucleic Acid Therapeutics

○ **Executive Summary / Investment Rational**

Aposense has developed a universal platform entitled Molecular Nano-Motors for intracellular delivery of genetic drugs based on a novel MOA. Robust efficacy has been demonstrated in numerous animal models including targeted delivery into macrophages upon IV administration.

Aposense's management has demonstrated exceptional leadership in guiding the growth of the company, successfully overseeing several investment rounds, and executing significant out-licensing deals.

○ **Core Technology**

The therapeutic potential of nucleic acid drugs has been limited by the problem of intracellular delivery. Aposense's unique approach exploits a large electrical dipole moment inherent in all phospholipid bilayer membranes. Knockdown of cellular genes in a wide range of cells and efficacy in several clinically relevant animal models has been demonstrated including targeted delivery into macrophages upon IV administration.

○ **Product Profile/Pipeline**

siRNA respiratory viral and local pulmonary platforms: Covid program ready for FIH. RSV and Influenza programs are in preclinical development. CF and IPF programs are post in vivo POC.

siRNA macrophage targeting is in preclinical development.

siRNA targeted delivery upon IV administration and delivery of mRNA financed by the Gates foundation.

Intracellular delivery of peptides in collaboration with big pharma.

○ **Business Strategy**

Aposense is a platform technology company addressing the biggest unmet need in the RNA space: intracellular delivery and specifically delivery to tissues beyond the liver. Our own pipeline development of leading assets will be combined with partnering deals, including out-licensing and co-development. This will allow for rapid implementation of the MNM technology across multiple therapeutic areas and modalities.

○ **What's Next?**

Aposense's Covid program will enter soon into clinical trials. Aposense also intends to develop further siRNA applications in additional therapeutic areas and unlock the potential of the technology for larger cargos. In addition, Aposense will expand the MNM technology platform for amino acid-based drugs.

Aposense plan to extend the team and in-house capabilities after next investment round.